Changes Are Afoot: The Prosecution and Litigation Landscape Post KSR and the New Continuation Rules
August 8, 2007
From the U.S. Supreme Court’s decision in KSR v. Teleflex to the recent change in the continuation rules, it is clear that the ways in which patents are prosecuted and litigated will need to change. Cases including KSR, Apotex v. Pfizer, and its progeny have had significant impact on various industries warranting a deeper look at how it will affect company strategies. Foley hosted an in-depth discussion and analysis of the case law in the wake of KSR and how the new U.S. Patent and Trademark Office rules will impact the ability to obtain and enforce patents.
This conference looked at:
- What drafting styles may be problematic
- Prosecution and continuation strategies related to new Patent Office rules, including:
- Limiting number of continuation applications
- Limiting number of claims in each patent application
- Gathering evidence at an early stage to ward off an obviousness challenge
- Using experts to bolster obviousness or non-obviousness arguments
- What industries are winning or losing the battle on obviousness
- Best practices for both the plaintiff/patent owner as well as defendant/accused infringer
People
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.